• PRF Technologies reported positive head-to-head preclinical results for PRF-110, its extended-release ropivacaine formulation for post-surgical pain.
• Results were presented in the announcement, not flagged for a future scientific meeting.
• PRF-110 delivered sustained pain relief over 72 hours comparable to ZYNRELEF in a pig incisional pain model.
• The outcome supported PRF-110’s single-dose, NSAID-free profile, positioning it as a potential non-opioid alternative for wound-bed administration.
• PRF plans to use the data to guide next development steps and regulatory strategy for PRF-110.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PRF Technologies Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605260830PRIMZONEFULLFEED9725828) on May 26, 2026, and is solely responsible for the information contained therein.